Studies from Tsinghua University in the Area of Cancer Reported (Mfolfox-haic Plus Lenvatinib+pd-1 Inhibitors Versus Gc/gs/ Gemox Chemotherapy As a First Line Therapy for Advanced Biliary Tract Cancer: a Single-center Retrospective Cohort Study).

A retrospective cohort study conducted at Tsinghua University in Beijing, China, compared the efficacy of a novel treatment regimen for advanced biliary tract cancer (BTC) with standard chemotherapy options. The study found that the novel regimen, which included hepatic artery infusion chemotherapy with mFOLFOX-HAIC, lenvatinib, and PD-1 inhibitors, demonstrated superior progression-free survival and overall survival compared to standard regimens. The research concluded that the new treatment appears to be safe and well-tolerated for advanced BTC patients. [Extracted from the article]